SCHEMBL21725633

SCHEMBL21725633

CC(C)OC(c1ccccc1)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.39
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TAAR1 Q96RJ0 3/20 0.38
SLC6A3 Q01959 2/20 0.37
SLC6A4 P31645 2/20 0.37
CACNA1F O60840 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
ADRA2B P18089 1/20 0.37
CHRM3 P20309 1/20 0.37
ADRA1A P35348 1/20 0.37
HRH1 P35367 1/20 0.37
OPRK1 P41145 1/20 0.37
CACNA1D Q01668 1/20 0.37
KCNH2 Q12809 1/20 0.37
CACNA1S Q13698 1/20 0.37
CACNA1C Q13936 1/20 0.37
SCN5A Q14524 1/20 0.37
AOC3 Q16853 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7438325 0.89 ATM (0.41) RIPK1ATML3MBTL1TAAR1SLC6A3
SCHEMBL22432527 0.83 SLC6A4 (0.39) RIPK1ATML3MBTL1SLC6A3SLC6A4
SCHEMBL21725624 0.81 NPSR1 (0.41) RIPK1L3MBTL1TAAR1ADRA2AADRA2C
SCHEMBL21725638 0.81 NPSR1 (0.41) RIPK1L3MBTL1TAAR1ADRA2AADRA2C
SCHEMBL2127629 0.79 ATM (0.41) RIPK1ATML3MBTL1TAAR1SLC6A3
SCHEMBL9275847 0.77 RIPK1 (0.37) RIPK1ATML3MBTL1TAAR1SLC6A3
SCHEMBL14663964 0.77 ATM (0.40) RIPK1ATML3MBTL1TAAR1SLC6A3
SCHEMBL11911981 0.77 ATM (0.40) RIPK1ATML3MBTL1TAAR1SLC6A3
SCHEMBL12344306 0.77 ATM (0.40) RIPK1ATML3MBTL1TAAR1SLC6A3
SCHEMBL7701248 0.76 ATM (0.39) RIPK1ATML3MBTL1TAAR1SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2021-04-20 US disclosed
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-09-08 US disclosed
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-31 US disclosed
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R RIPK1 4491/4885ATM 4610/4885L3MBTL1 4237/4885
US-10562884-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R RIPK1 4491/4885ATM 4610/4885L3MBTL1 4237/4885
US-10766877-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R RIPK1 4491/4885ATM 4610/4885L3MBTL1 4237/4885
US-10981894-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R RIPK1 4491/4885ATM 4610/4885L3MBTL1 4237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.